Abstract No. 40: CT Guided Translateral Approach Via the Space Between Carotid Sheath and Vertebral Artery to Metastatic Involved C2 for Percutaneous Vertebroplasty

2009 ◽  
Vol 20 (2) ◽  
pp. S17
Author(s):  
L. Zhengyin
2012 ◽  
Vol 5;15 (5;9) ◽  
pp. E733-E741
Author(s):  
Zheng-Yin Liao

Background: The clinical management of spinal hemangiomas and osteolytic metastases involving the upper cervical spine (C1-C3) is challenging. Symptoms vary from simple vertebral pain to progressive neurological deficits. Surgery and radiotherapy have been the treatment options for years. Surgery, however, can result in complications, such as hemorrhage, and may be counter-indicated when the treatment goal is primarily palliative due to multiple metastases, an unfavorable prognosis and/or a poor performance state. On the other hand, radiotherapy carries the risk of inducing secondary sarcomas or producing radionecrosis. Percutaneous vertebroplasty (PVP) was recently introduced as an alternative for treating patients in whom surgery and radiotherapy are counter-indicated. As of yet, there are few PVP case reports. Objective: This study aimed to evaluate the safety and efficacy of PVP using a computed tomography (CT)-guided translateral approach via the space between the carotid sheath and vertebral artery for hemangiomas or metastatic lesions at C1-C3 under local anesthesia. Study Design: CT-guided PVP was performed in 15 patients with hemangiomas or metastatic lesions at C1-C3 and clinical outcomes were evaluated. Setting: An interventional therapy group at a medical center in a major Chinese city. Methods: Fifteen consecutive patients had a total of 15 cervical vertebral bodies treated with CT-guided PVP via a translateral approach. The patients were followed up for a mean postoperative period of 8.3 months (range, 1-40 months). Pain status was assessed using a visual analog scale (VAS). The presence of complications was assessed preoperatively (baseline) and at 24 hours, 2 weeks, and one, 3, 6, 12 and 24 months postoperatively, or until the patient died or was lost to follow-up. Results: Fifteen consecutive patients were successfully treated with CT-guided PVP via a translateral approach. Their mean VAS score decreased from 7.7 ± 2.9 preoperatively to 1.4 ± 1.5 by the 24 hour postoperative time point, and was 1.2 ± 1.3 at 2 weeks, 1.2 ± 1.3 at one month, 1.4 ± 1.3 at 3 months, 0.6 ± 0.9 at 6 months, 0.3 ± 0.5 at 12 months, and 0 at 24 months after the procedure. The mean VAS score at all of the postoperative time points differed significantly from the preoperative baseline score (P < 0.05). No severe complications were observed. Mild complications included 2 cases (13.3%) of asymptomatic cement leakage into the epidural space, one case (6.67%) of anterior leakage from the vertebral body, and 2 cases (13.3%) of paravertebral leakage. Limitations: This was an observational study with a relatively small sample size. Conclusions: The safety and efficacy of CT-guided PVP using a translateral approach via the space between the carotid sheath and vertebral artery were demonstrated in patients with hemangioma or metastasis in the upper cervical spine. CT-guided PVP via a translateral approach should become a treatment option for such patients. Key words: CT-guided percutaneous vertebroplasty, upper cervical spine, translateral approach, hemangioma, osteolytic metastasis, pain


2014 ◽  
Vol 20 (5) ◽  
pp. 591-602 ◽  
Author(s):  
Héctor Manuel Barragán-Campos ◽  
Anne-Laurence Le Faou ◽  
Michèle Rose ◽  
Alain Livartowski ◽  
Marianne Doz ◽  
...  

Percutaneous vertebroplasty (PV) is a therapeutic option in patients with vertebral metastases (VM). However its efficacy in pain relief, improvement in quality of life and safety in patients with VM from breast cancer has not been reported. We present a longitudinal retrospective study of 31 consecutively treated female patients with VM from breast cancer where 88 vertebrae were treated in 44 sessions of PV, in which osteolytic, osteoblastic and mixed lesions were recorded. The visual analogue pain scale (VAS) was used to evaluate pain pre-PV, at one, three, six and 12 months post-PV. The Eastern Cooperative Group (ECOG) performance status scale was used at the same time intervals to measure quality of life: 90.3% pain relief was identified with a VAS reduction from 5.7 ± 2.0 pre-PV to 2.9 ± 2.2 post-PV at one-month follow-up (p<0.001) and 0.6 ± 1.0 at 12-month follow-up (p<0.001). In our series 48.4% of patients were classified as having an ECOG grade 0 and 1 pre-PV, which increased to 80.8% at the 12-month follow-up. While 22.6% of the patients were classified at ECOG grades 3 and 4 pre-PV, this improved to 0% at 12 months follow-up. The morbidity rate for this procedure was 12.9% immediately and only 3.2% at 30 days post-PV with all complications being resolved medically or with CT-guided infiltration. PV is a safe procedure with a high efficacy in pain relief, and improvement of quality of life in patients with diverse types of VM from breast cancer.


2003 ◽  
Vol 23 (1) ◽  
pp. 1-6 ◽  
Author(s):  
Shima TSUTANI ◽  
Yasuhiro MAEHARA ◽  
Hideki FUKUDA ◽  
Masashi KAWAMOTO ◽  
Osafumi YUGE

2008 ◽  
Vol 113 (1) ◽  
pp. 114-133 ◽  
Author(s):  
R. Caudana ◽  
L. Renzi Brivio ◽  
L. Ventura ◽  
E. Aitini ◽  
U. Rozzanigo ◽  
...  

2009 ◽  
Vol 10 (2) ◽  
pp. 185 ◽  
Author(s):  
Ju-Yong Seong ◽  
Jin-Sung Kim ◽  
Byungjoo Jung ◽  
Sang-Ho Lee ◽  
Ho Yeong Kang

2020 ◽  
Vol 55 (1) ◽  
pp. 11-16
Author(s):  
C. Teriitehau ◽  
H. Rabeh ◽  
E. Pessis ◽  
Q. Sénéchal ◽  
F. Besse ◽  
...  

To assess the impact of a computer assisted navigation system (CAN) (CT-Navigation™ IMACTIS, France) on patient radiation doses during percutaneous CT vertebroplasty a retrospective comparative trial was performed and included 37 patients requiring percutaneous vertebroplasty. This study was approved by CCN (Centre Cardiologique du Nord, Saint-Denis, France) ethical committee; all patients provided informed consent. All procedures were conducted in the interventional radiology department at CCN, by an experienced single radiologist using the same model and CT scan with identical parameters. The interventional dose length product (IDLP), representing the absorbed dose by the length of explored organs during the needle insertion phase, was compared in 15 consecutive patients who underwent a conventional procedure (CT control group), and in 22 patients who underwent CAN CT vertebroplasty (CAN group). The IDLP difference between the two groups was evaluated using Mann–Whitney U test. The median IDLP dose for the CAN group was 305.6 mGy.cm [182.3; 565.4], representing a reduction by a 3.2 factor compared with that of the conventional CT group (median 975.2 mGy.cm [568.3; 1077.1]; p < 0.001). The median procedure duration for the CAN group was 50 min [35; 60] vs. 100 min [82; 100] in the CT group (p < 0.001), representing a 50% reduction. In experienced hands, use of a CT-Navigation™ system (IMACTIS®) significantly reduced both patient radiation dose and procedure duration when compared to conventional CT guided percutaneous vertebroplasty.


Sign in / Sign up

Export Citation Format

Share Document